APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Central Nervous System (CNS) Stimulant Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Central Nervous System (CNS) Stimulant Drugs Market Outlook and Growth Opportunities 2026

Report ID 173976390420 December 2025199 pages

Choose your research edition.

Industry ResearchCentral Nervous System (CNS) Stimulant Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Central Nervous System (CNS) Stimulant Drugs Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Central Nervous System (CNS) Stimulant Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Central Nervous System (CNS) Stimulant Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Central Nervous System (CNS) Stimulant Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Central Nervous System (CNS) Stimulant Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Central Nervous System (CNS) Stimulant Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Central Nervous System (CNS) Stimulant Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Central Nervous System (CNS) Stimulant Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Central Nervous System (CNS) Stimulant Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Central Nervous System (CNS) Stimulant Drugs market include Takeda Pharmaceuticals, Sanofi, Thermo Fisher Scientific, Johnson and Johnson, Novartis, Merck, Roche, Eli Lilly and Company and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Central Nervous System (CNS) Stimulant Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Central Nervous System (CNS) Stimulant Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Central Nervous System (CNS) Stimulant Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Central Nervous System (CNS) Stimulant Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Central Nervous System (CNS) Stimulant Drugs Segment by Company

Takeda Pharmaceuticals

Sanofi

Thermo Fisher Scientific

Johnson and Johnson

Novartis

Merck

Roche

Eli Lilly and Company

Pfizer

GlaxoSmithKline

Biogen

Shire

Perdue Pharma

Celltech

Astellas Pharma

Central Nervous System (CNS) Stimulant Drugs Segment by Type

Cocaine

Caffeine

Amphetamine

Others

Central Nervous System (CNS) Stimulant Drugs Segment by Application

Attention Deficit Hyperactivity Disorder (ADHD)

Narcolepsy

Others

Central Nervous System (CNS) Stimulant Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Central Nervous System (CNS) Stimulant Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Central Nervous System (CNS) Stimulant Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Central Nervous System (CNS) Stimulant Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Central Nervous System (CNS) Stimulant Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Stimulant Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Stimulant Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Stimulant Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Central Nervous System (CNS) Stimulant Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Central Nervous System (CNS) Stimulant Drugs industry.

Chapter 3: Detailed analysis of Central Nervous System (CNS) Stimulant Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Central Nervous System (CNS) Stimulant Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Central Nervous System (CNS) Stimulant Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Central Nervous System (CNS) Stimulant Drugs Industry Trends Table 2. Central Nervous System (CNS) Stimulant Drugs Industry Drivers Table 3. Central Nervous System (CNS) Stimulant Drugs Industry Opportunities and Challenges Table 4. Central Nervous System (CNS) Stimulant Drugs Industry Restraints Table 5. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Central Nervous System (CNS) Stimulant Drugs Revenue Share by Company (2021-2026) Table 7. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Company (tons) & (2021-2026) Table 8. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Central Nervous System (CNS) Stimulant Drugs Average Price (US$/ton) of Company (2021-2026) Table 10. Global Central Nervous System (CNS) Stimulant Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Central Nervous System (CNS) Stimulant Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Central Nervous System (CNS) Stimulant Drugs Company, Product Type & Application Table 13. Global Central Nervous System (CNS) Stimulant Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Central Nervous System (CNS) Stimulant Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Cocaine Table 18. Significant Companies of Caffeine Table 19. Significant Companies of Amphetamine Table 20. Significant Companies of Others Table 21. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (tons) Table 22. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Type (2021-2026) & (tons) Table 23. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Type (2027-2032) & (tons) Table 24. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume Share by Type (2021-2026) Table 25. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume Share by Type (2027-2032) Table 26. Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type (2021-2026) Table 30. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Attention Deficit Hyperactivity Disorder (ADHD) Table 32. Significant Companies of Narcolepsy Table 33. Significant Companies of Others Table 34. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (tons) Table 35. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Application (2021-2026) & (tons) Table 36. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Application (2027-2032) & (tons) Table 37. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application (2021-2026) Table 43. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application (2027-2032) Table 44. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Table 45. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2021-2026) & (tons) Table 46. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Region (2021-2026) Table 47. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2027-2032) & (tons) Table 48. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Region (2027-2032) Table 49. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Region (2021-2026) Table 52. Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Region (2027-2032) Table 54. Global Central Nervous System (CNS) Stimulant Drugs Market Average Price (US$/ton) by Region (2021-2026) Table 55. Global Central Nervous System (CNS) Stimulant Drugs Market Average Price (US$/ton) by Region (2027-2032) Table 56. Global Central Nervous System (CNS) Stimulant Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Table 57. Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026) & (tons) Table 59. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2021-2026) Table 60. Global Central Nervous System (CNS) Stimulant Drugs Sales by Country (2027-2032) & (tons) Table 61. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2027-2032) Table 62. Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Market Share by Country (2027-2032) Table 66. Takeda Pharmaceuticals Company Information Table 67. Takeda Pharmaceuticals Business Overview Table 68. Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 69. Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 70. Takeda Pharmaceuticals Recent Development Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 74. Sanofi Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 75. Sanofi Recent Development Table 76. Thermo Fisher Scientific Company Information Table 77. Thermo Fisher Scientific Business Overview Table 78. Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 79. Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 80. Thermo Fisher Scientific Recent Development Table 81. Johnson and Johnson Company Information Table 82. Johnson and Johnson Business Overview Table 83. Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 84. Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 85. Johnson and Johnson Recent Development Table 86. Novartis Company Information Table 87. Novartis Business Overview Table 88. Novartis Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 89. Novartis Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 90. Novartis Recent Development Table 91. Merck Company Information Table 92. Merck Business Overview Table 93. Merck Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 94. Merck Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 95. Merck Recent Development Table 96. Roche Company Information Table 97. Roche Business Overview Table 98. Roche Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 99. Roche Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 100. Roche Recent Development Table 101. Eli Lilly and Company Company Information Table 102. Eli Lilly and Company Business Overview Table 103. Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 104. Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 105. Eli Lilly and Company Recent Development Table 106. Pfizer Company Information Table 107. Pfizer Business Overview Table 108. Pfizer Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 109. Pfizer Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 110. Pfizer Recent Development Table 111. GlaxoSmithKline Company Information Table 112. GlaxoSmithKline Business Overview Table 113. GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 114. GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 115. GlaxoSmithKline Recent Development Table 116. Biogen Company Information Table 117. Biogen Business Overview Table 118. Biogen Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 119. Biogen Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 120. Biogen Recent Development Table 121. Shire Company Information Table 122. Shire Business Overview Table 123. Shire Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 124. Shire Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 125. Shire Recent Development Table 126. Perdue Pharma Company Information Table 127. Perdue Pharma Business Overview Table 128. Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 129. Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 130. Perdue Pharma Recent Development Table 131. Celltech Company Information Table 132. Celltech Business Overview Table 133. Celltech Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 134. Celltech Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 135. Celltech Recent Development Table 136. Astellas Pharma Company Information Table 137. Astellas Pharma Business Overview Table 138. Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 139. Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 140. Astellas Pharma Recent Development Table 141. Key Raw Materials Table 142. Raw Materials Key Suppliers Table 143. Central Nervous System (CNS) Stimulant Drugs Distributors List Table 144. Central Nervous System (CNS) Stimulant Drugs Customers List Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Central Nervous System (CNS) Stimulant Drugs Product Image Figure 2. Global Central Nervous System (CNS) Stimulant Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Central Nervous System (CNS) Stimulant Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Central Nervous System (CNS) Stimulant Drugs Sales (2021-2032) & (tons) Figure 5. Global Central Nervous System (CNS) Stimulant Drugs Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Central Nervous System (CNS) Stimulant Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Cocaine Image Figure 10. Caffeine Image Figure 11. Amphetamine Image Figure 12. Others Image Figure 13. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (tons) Figure 14. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type (2021-2032) Figure 19. Attention Deficit Hyperactivity Disorder (ADHD) Image Figure 20. Narcolepsy Image Figure 21. Others Image Figure 22. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (tons) Figure 23. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Central Nervous System (CNS) Stimulant Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Figure 29. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Central Nervous System (CNS) Stimulant Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Central Nervous System (CNS) Stimulant Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Central Nervous System (CNS) Stimulant Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Central Nervous System (CNS) Stimulant Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Central Nervous System (CNS) Stimulant Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Central Nervous System (CNS) Stimulant Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Cocaine
  • Caffeine
  • Amphetamine
  • Others
Applications
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Narcolepsy
  • Others
Companies covered
  • Takeda Pharmaceuticals
  • Sanofi
  • Thermo Fisher Scientific
  • Johnson and Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Shire
  • Perdue Pharma
  • Celltech
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Central Nervous System (CNS) Stimulant Drugs Market Dynamics
  1. 2.1 Central Nervous System (CNS) Stimulant Drugs Industry Trends
  2. 2.2 Central Nervous System (CNS) Stimulant Drugs Industry Drivers
  3. 2.3 Central Nervous System (CNS) Stimulant Drugs Industry Opportunities and Challenges
  4. 2.4 Central Nervous System (CNS) Stimulant Drugs Industry Restraints
3 Central Nervous System (CNS) Stimulant Drugs Market by Company
  1. 3.1 Global Central Nervous System (CNS) Stimulant Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Central Nervous System (CNS) Stimulant Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Central Nervous System (CNS) Stimulant Drugs Company Ranking (2024-2026)
  6. 3.6 Global Central Nervous System (CNS) Stimulant Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Central Nervous System (CNS) Stimulant Drugs Company Product Type and Application
  8. 3.8 Global Central Nervous System (CNS) Stimulant Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Central Nervous System (CNS) Stimulant Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Central Nervous System (CNS) Stimulant Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Central Nervous System (CNS) Stimulant Drugs Market by Type
  1. 4.1 Central Nervous System (CNS) Stimulant Drugs Type Introduction
  2. 4.1.1 Cocaine
  3. 4.1.2 Caffeine
  4. 4.1.3 Amphetamine
  5. 4.1.4 Others
  6. 4.2 Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Type
  7. 4.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Type
  11. 4.3.1 Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type (2021-2032)
5 Central Nervous System (CNS) Stimulant Drugs Market by Application
  1. 5.1 Central Nervous System (CNS) Stimulant Drugs Application Introduction
  2. 5.1.1 Attention Deficit Hyperactivity Disorder (ADHD)
  3. 5.1.2 Narcolepsy
  4. 5.1.3 Others
  5. 5.2 Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Application
  6. 5.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Application
  10. 5.3.1 Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application (2021-2032)
6 Central Nervous System (CNS) Stimulant Drugs Regional Sales and Value Analysis
  1. 6.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2027-2032)
  5. 6.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Central Nervous System (CNS) Stimulant Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Central Nervous System (CNS) Stimulant Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Central Nervous System (CNS) Stimulant Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Central Nervous System (CNS) Stimulant Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Central Nervous System (CNS) Stimulant Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Country, 2025 VS 2032
7 Central Nervous System (CNS) Stimulant Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Country (2027-2032)
  6. 7.4 Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Central Nervous System (CNS) Stimulant Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Central Nervous System (CNS) Stimulant Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Central Nervous System (CNS) Stimulant Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Thermo Fisher Scientific
  14. 8.3.1 Thermo Fisher Scientific Company Information
  15. 8.3.2 Thermo Fisher Scientific Business Overview
  16. 8.3.3 Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  18. 8.3.5 Thermo Fisher Scientific Recent Developments
  19. 8.4 Johnson and Johnson
  20. 8.4.1 Johnson and Johnson Company Information
  21. 8.4.2 Johnson and Johnson Business Overview
  22. 8.4.3 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  24. 8.4.5 Johnson and Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Merck Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Roche Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Eli Lilly and Company
  44. 8.8.1 Eli Lilly and Company Company Information
  45. 8.8.2 Eli Lilly and Company Business Overview
  46. 8.8.3 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  48. 8.8.5 Eli Lilly and Company Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 GlaxoSmithKline
  56. 8.10.1 GlaxoSmithKline Company Information
  57. 8.10.2 GlaxoSmithKline Business Overview
  58. 8.10.3 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  60. 8.10.5 GlaxoSmithKline Recent Developments
  61. 8.11 Biogen
  62. 8.11.1 Biogen Company Information
  63. 8.11.2 Biogen Business Overview
  64. 8.11.3 Biogen Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Biogen Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  66. 8.11.5 Biogen Recent Developments
  67. 8.12 Shire
  68. 8.12.1 Shire Company Information
  69. 8.12.2 Shire Business Overview
  70. 8.12.3 Shire Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Shire Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  72. 8.12.5 Shire Recent Developments
  73. 8.13 Perdue Pharma
  74. 8.13.1 Perdue Pharma Company Information
  75. 8.13.2 Perdue Pharma Business Overview
  76. 8.13.3 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  78. 8.13.5 Perdue Pharma Recent Developments
  79. 8.14 Celltech
  80. 8.14.1 Celltech Company Information
  81. 8.14.2 Celltech Business Overview
  82. 8.14.3 Celltech Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Celltech Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  84. 8.14.5 Celltech Recent Developments
  85. 8.15 Astellas Pharma
  86. 8.15.1 Astellas Pharma Company Information
  87. 8.15.2 Astellas Pharma Business Overview
  88. 8.15.3 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  90. 8.15.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Central Nervous System (CNS) Stimulant Drugs Value Chain Analysis
  2. 9.1.1 Central Nervous System (CNS) Stimulant Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Central Nervous System (CNS) Stimulant Drugs Sales Mode & Process
  6. 9.2 Central Nervous System (CNS) Stimulant Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Central Nervous System (CNS) Stimulant Drugs Distributors
  9. 9.2.3 Central Nervous System (CNS) Stimulant Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst